Trial Profile
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 Years of Age
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 19 Jan 2024
Price :
$35
*
At a glance
- Drugs Elasomeran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Acronyms TeenCOVE
- Sponsors Moderna Therapeutics
- 24 Aug 2023 Planned End Date changed from 3 Mar 2025 to 9 Dec 2024.
- 24 Aug 2023 Planned primary completion date changed from 8 Aug 2024 to 9 Jun 2024.
- 24 Aug 2023 Status changed from recruiting to active, no longer recruiting.